Products All Cellular Research Metabolic Research Peptide Compounds Research Blends Lab supplies Longevity Research ADVBioLabs AOD-9604 5mg Research Peptide COA Verified High Purity AOD5 Research Use Only Metabolic Research Metabolic Research AOD-9604 5mg Research Peptide COA Verified High Purity $80.00 Fragment peptide supplied in lyophilized powder form
Molecular Composition and Characteristics Component 1: BPC-157 (synthetic pentadecapeptide) Component 2: TB-500 (thymosin beta-4 analogue) Referenced Component: CAS 89030-95-5 for analytical traceability Structure: Linear synthetic peptide chains supplied as a blended formulation Dose Format: High-concentration 30mg blended vial Stability and Storage Characteristics Supplied as a lyophilised powder for optimal stability Recommended storage temperature: 20C Sensitive to moisture, light exposure, and elevated temperatures Predictable degradation above room temperature Reconstituted solutions generally stable for 2448 hours under refrigeration Reconstitution Compatibility Bacteriostatic water Sterile saline Acid-adjusted buffer systems Selected analytical-grade organic solvents Technical Specifications product Name BPC-157 + TB-500 Blend 30mg cas 137525-51-0, 77591-33-4, 89030-95-5 purity 99% (HPLC verified) unit Size 30 mg blended vial form Lyophilised peptide blend synthesis Solid-Phase Peptide Synthesis (SPPS) analytical HPLC, Mass Spectrometry, UV Spectrophotometry molecular Structure Linear synthetic peptide chains stability High under recommended laboratory storage Quality Control and Documentation HPLC purity confirmation Mass Spectrometry molecular identity verification UV spectrophotometric concentration analysis Batch consistency and reproducibility testing Endotoxin and microbial screening Regulatory Statement BPC-157 + TB-500 Blend 30mg is supplied strictly for laboratory research and scientific investigation
Understanding whether semaglutide expires after 28 days requires knowing which formulation you have, because Ozempic and Wegovy have different timelines
Combination Weight Loss (CagriSema) Extensive Research The Phase 3 REDEFINE 1 trial demonstrated that CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) produced mean weight loss of 20.4% at 68 weeks in 3,417 adults with obesity or overweight without diabetes, compared to 14.9% with semaglutide alone, 11.5% with cagrilintide alone, and 3.0% with placebo
